Clinical Trial Search

Primary: 3-Year Event-Free Survival (EFS) — 68 Participants

Primary: 3-year Overall Survival Rate of Patients With Relapsed ALL — 94.4; 55.5; 72.63 percentage of participants — p=0.035

Primary: Overall Event-free Survival (EFS) — 87.3 Percentage of Participants

Primary: Kaplan Meier Estimate: Event-Free Survival (EFS; Primary Analysis) — 7.4; NA months — p=< 0.001

Primary: Percentage of Participants With Complete Remission/Complete Remission With Partial Hematological Recovery (CR/CRh*) During the First Two Treatment Cycles — 35.6…

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 69 Participants

Primary: DFS of Non-DS HR Post-induction Patients Receiving Intrathecal (IT) Methotrexate (MTX) Compared With Patients Receiving Intrathecal Triple Therapy (ITT) on a Modified…

Primary: Phase 1b: Number of Participants With Dose-limiting Toxicities — 0; 0 Participants

Primary: Phase I: Number of Participants With Dose-limiting Toxicities (DLTs) — 0; 1; 2; 1 participants

Primary: Remission Re-induction (CR2) Rate — .646; .660 proportion of participants

Primary: Probability of Event-free Survival (EFS) — 91.7; 71.4; 100; 86.96 percentage of event-free patients

Primary: Response Rate (RR) — 11 Participants

Primary: Best Overall Response Rate (ORR) — 6; 0; 1; 0 Participants

Primary: Occurrence of a Dose-Limiting Toxicity (Phase 1) — 0; 1; 4; 5 Participants

Primary: 3-year Event-free Survival (EFS) Rate — 66.0 Percentage of Participants — p=0.032

Primary: Event-free Survival Rate (EFS) — 21.3 Months

Primary: Complete Response Rate — 89 percentage of patients

Primary: Continuous Complete Remission at 1 Year — 21 participants

Primary: Progression-free Survival (PFS) — 4.3; 14.5 Months

Primary: Disease Free Survival (DFS) in Average Risk (AR) Patients Based on the Methotrexate Dose Randomization — 95.05; 94.17 percent probability

Primary: Percentage of Participants Reaching Disease Free Survival — 45.8 percentage of participants

Primary: Disease Free Survival — 1.7 years

Primary: Event-free Survival (EFS) for SR-Average ALL Patients — 83.82; 88.89; 88.34; 90.51 percent probability

Primary: Percent Probability for Event-free Survival (EFS) for Patients on Arm C at Dose Level 2 (DL2) — 35.82 percentage probability

Primary: Percentage of Participants With Continuous Complete Remission of Patients Receiving High-dose and Conventional Dose PEG-asparaginase. — 91.6; 90.7 Percentage of…

Primary: Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment — 71.4…

Primary: Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment — 42.9…

Primary: Phase I: Incidence of Any DLT Attributed to DT2219 in the First Cycle — 1; 3; 0 events

Primary: Percentage of Participants With a Hematological Response of Complete Remission (CR) or Complete Remission With Partial Hematological Recovery (CRh*) During the First 2…

Primary: Number of Participants Who Received Preparative Chemotherapy Followed by Cluster of Differentiation (CD)19-Chimeric Antigen Receptor (CAR): CD19 CAR T-cells With < Grade…